{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T17:33:47Z","timestamp":1776447227167,"version":"3.51.2"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,16]]},"DOI":"10.7759\/cureus.58408","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T17:40:01Z","timestamp":1713289201000},"source":"Crossref","is-referenced-by-count":1,"title":["Treatment of Depression in Adolescents With Myasthenia Gravis"],"prefix":"10.7759","author":[{"given":"Mariana I","family":"Arce","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine A","family":"Breetz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine A","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.spen.2017.04.003","article-title":"Pediatric myasthenia gravis","volume":"24","author":"Peragallo JH","year":"2017","unstructured":"Peragallo JH. Pediatric myasthenia gravis. Semin Pediatr Neurol. 2017, 24:116-21. 10.1016\/j.spen.2017.04.003","journal-title":"Semin Pediatr Neurol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2840","article-title":"Prevalence of depression and anxiety among myasthenia gravis (MG) patients: a systematic review and meta-analysis","volume":"13","author":"Nadali J","year":"2023","unstructured":"Nadali J, Ghavampour N, Beiranvand F, et al.. Prevalence of depression and anxiety among myasthenia gravis (MG) patients: a systematic review and meta-analysis. Brain Behav. 2023, 13:e2840. 10.1002\/brb3.2840","journal-title":"Brain Behav"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-018-8837-4","article-title":"Neurological diseases and risk of suicide attempt: a case-control study","volume":"265","author":"Eliasen A","year":"2018","unstructured":"Eliasen A, Dalhoff KP, Horwitz H. Neurological diseases and risk of suicide attempt: a case-control study. J Neurol. 2018, 265:1303-9. 10.1007\/s00415-018-8837-4","journal-title":"J Neurol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-09767-7","article-title":"Depression in myasthenia gravis: a heterogeneous and intriguing entity","volume":"267","author":"Gavrilov YV","year":"2020","unstructured":"Gavrilov YV, Alekseeva TM, Kreis OA, Valko PO, Weber KP, Valko Y. Depression in myasthenia gravis: a heterogeneous and intriguing entity. J Neurol. 2020, 267:1802-11. 10.1007\/s00415-020-09767-7","journal-title":"J Neurol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2018.09.021","article-title":"Prevalence and treatment of depression, anxiety, and conduct problems in US children","volume":"206","author":"Ghandour RM","year":"2019","unstructured":"Ghandour RM, Sherman LJ, Vladutiu CJ, Ali MM, Lynch SE, Bitsko RH, Blumberg SJ. Prevalence and treatment of depression, anxiety, and conduct problems in US children. J Pediatr. 2019, 206:256-67. 10.1016\/j.jpeds.2018.09.021","journal-title":"J Pediatr"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/aap.12005","article-title":"Neuromuscular blocking effect of fluoxetine and its interaction with rocuronium","volume":"33","author":"Patel JC","year":"2013","unstructured":"Patel JC, Barvaliya MJ, Patel TK, Tripathi CB. Neuromuscular blocking effect of fluoxetine and its interaction with rocuronium. Auton Autacoid Pharmacol. 2013, 33:17-24. 10.1111\/aap.12005","journal-title":"Auton Autacoid Pharmacol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14773","article-title":"Worsening of myasthenia due to antiepileptic, antipsychotic, antidepressant, and sedative medication: an estimation of risk based on reporting frequency","volume":"28","author":"Trillenberg P","year":"2021","unstructured":"Trillenberg P, Katalinic A, Junghanns K, Thern J. Worsening of myasthenia due to antiepileptic, antipsychotic, antidepressant, and sedative medication: an estimation of risk based on reporting frequency. Eur J Neurol. 2021, 28:2349-56. 10.1111\/ene.14773","journal-title":"Eur J Neurol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/230849-treatment-of-depression-in-adolescents-with-myasthenia-gravis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T17:40:06Z","timestamp":1713289206000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/230849-treatment-of-depression-in-adolescents-with-myasthenia-gravis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,16]]},"references-count":7,"URL":"https:\/\/doi.org\/10.7759\/cureus.58408","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,16]]}}}